An analysis of the efficacy of calcitonin gene-related peptide inhibitors on the treatment of migraine in adults
The CGRP monoclonal antibodies are the first class of medication developed specifically for migraine prevention, in contrast to previous preventative medications, that were in the anti-hypertensive, anti-epileptic and anti-depressant class. There are two notable divisions within the CGRP inhibitor...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/43382 |